Delivery Order HHSN268201600013I-75N92019F00074
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a National Cancer Institute-designated comprehensive cancer center in Tampa, Florida, was awarded a delivery order valued at $525,665.30 by the National Heart, Lung, and Blood Institute under the Production Assistance for Cellular Therapies–Cell Processing Facilities (PACT-CPF) master IDIQ vehicle. This contract, issued on October 31, 2018, with completion targeted for June 1, 2020, calls for cell manufacturing and process...
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a non-profit, National Cancer Institute-designated comprehensive cancer center located in Tampa, Florida, was awarded a delivery order contract valued at $211,273.45 by the National Heart Lung and Blood Institute on December 3, 2018. This contract falls under the Production Assistance for Cellular Therapies – Cell Processing Facilities (PACT-CPF) master indefinite delivery, indefinite quantity vehicle and specifically supports...
- This contract was awarded by the National Institutes of Health (NIH) National Heart Lung and Blood Institute to the H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. for production assistance for cellular therapies (PACT) - cell processing facilities. The contract has a potential value of $488,251.00 and does not utilize a small business set-aside. It is a delivery order under the larger PACT-CPF master indefinite delivery/indefinite quantity (IDIQ) contract, which provides...
- This is a delivery order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a part of the U.S. Department of Health and Human Services, to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. The contract provides "Production Assistance for Cellular Therapies (PACT) - Cell Processing Facilities" with a ceiling value of $1,211,512.00 and a period of performance through June 30, 2021. This contract is not set aside and is part of the larger PACT-CPF...
- This is a delivery order awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center), a nonprofit cancer center in Tampa, Florida. The order is for "PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES CELL MANUFACTURING AND PROCESS DEVELOPMENT SERVICES FOR RSA PCT0002-02: LOVO PACT CENTER STUDY" and is part...
- This federal contract award was issued by the Department of Health and Human Services' National Institutes of Health National Heart Lung and Blood Institute to the H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. The $1,317,908.89 delivery order contract is for the "National Myelodysplastic Syndromes (MDS) Natural History Study - Central Laboratory and Biorepository." The contract has a completion date of June 29, 2018 and did not use any small business set-asides....
- This is a federal contract award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) located in Tampa, Florida. The contract, valued at $15,602,467.00, is focused on early therapeutic development with an emphasis on Phase II clinical trials. The contract is not set aside for any specific business type. Moffitt Cancer Center, a nonprofit, NCI-designated...
- This firm fixed-price purchase order was awarded by the National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. The $107,968 contract is for the acquisition of cancer biospecimens from the Moffitt Cancer Center to support a multi-ancestry genome-wide association study of lymphoid malignancies. The Moffitt Cancer Center is a nonprofit hospital and the only National...
- The National Institutes of Health National Heart Lung and Blood Institute awarded the University of Miami a $570,297 delivery order against the Production Assistance for Cellular Therapies - Cell Processing Facilities (PACT-CPF) master IDIQ contract. The order is for cell manufacturing and process development services to produce and test induced pluripotent stem cell cardiomyocyte banks in support of PCT009-02. Performance will take place in South Miami, Florida through March 2022. The...
- This federal contract award is for the Production Assistance for Cellular Therapies (PACT) - Cell Processing Facilities project, with the National Heart Lung and Blood Institute as the funding agency. The prime contractor is the University of Miami, a private non-profit research university that conducts a wide range of biomedical and healthcare research funded by federal agencies. The $1,016,451.61 contract provides cell manufacturing and process development services for induced pluripotent stem...
- HHSN268201600013IIndefinite Delivery Contract
- HHSN268201600013I-75N92019F00074Delivery Order
The National Heart Lung and Blood Institute awarded a delivery order valued at $761,385.23 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. on June 3, 2019, with completion targeted for March 31, 2022. This contract falls under the Production Assistance for Cellular Therapies–Cell Processing Facilities (PACT-CPF) master IDIQ vehicle and supports cell manufacturing and process development services for a Factor VIII TCR-engineered Treg cell product (PCT0025-01). The award was structured as a cost, no-fee delivery order with no small business set-aside and is being performed at Moffitt's Tampa, Florida facility. As a National Cancer Institute-designated comprehensive cancer center, H. Lee Moffitt Cancer Center brings substantial expertise in advanced cellular therapies and immunotherapy development to this engagement. The contract represents the federal government's investment in specialized cell processing capabilities and manufacturing infrastructure necessary to advance regenerative and cellular medicine initiatives. Moffitt's established track record in cancer research, clinical trial execution, and translational medicine positions the organization to deliver the technical expertise required for engineering and manufacturing this specialized Treg cell therapeutic product.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00004 | Close Out | $0 | 12/1/25 | |
| P00003 | Funding Only Action | ($82k) | 6/12/24 | |
| P00002 | Supplemental Agreement for work within scope | $0 | 5/26/21 | |
| P00001 | Supplemental Agreement for work within scope | $0 | 6/1/20 | |
| Not listed | Not listed | $843.7k | 6/3/19 |